286 related articles for article (PubMed ID: 26219488)
1. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
[TBL] [Abstract][Full Text] [Related]
2. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F
Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome.
Liu H; Xie S; Liang T; Ma L; Sun H; Dai H; Wang C
Eur Radiol; 2019 Oct; 29(10):5349-5357. PubMed ID: 30919069
[TBL] [Abstract][Full Text] [Related]
5. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
[TBL] [Abstract][Full Text] [Related]
6. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
Hervier B; Devilliers H; Stanciu R; Meyer A; Uzunhan Y; Masseau A; Dubucquoi S; Hatron PY; Musset L; Wallaert B; Nunes H; Maisonobe T; Olsson NO; Adoue D; Arlet P; Sibilia J; Guiguet M; Lauque D; Amoura Z; Hachulla E; Hamidou M; Benveniste O
Autoimmun Rev; 2012 Dec; 12(2):210-7. PubMed ID: 22771754
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
[TBL] [Abstract][Full Text] [Related]
8. Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study.
Rivero-Gallegos D; Mejía M; Rocha-González HI; Huerta-Cruz JC; Falfán-Valencia R; Ramos-Martínez E; Mateos-Toledo HN; Castillo-López MF; Rodríguez-Torres YK; Lira-Boussart V; Rojas-Serrano J
Clin Rheumatol; 2024 Jun; 43(6):1971-1978. PubMed ID: 38642252
[TBL] [Abstract][Full Text] [Related]
9. Evolution of Pulmonary Function in a Cohort of Patients with Interstitial Lung Disease and Positive for Antisynthetase Antibodies.
González-Pérez MI; Mejía-Hurtado JG; Pérez-Román DI; Buendía-Roldán I; Mejía M; Falfán-Valencia R; Mateos-Toledo HN; Rojas-Serrano J
J Rheumatol; 2020 Mar; 47(3):415-423. PubMed ID: 31203227
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
11. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
[TBL] [Abstract][Full Text] [Related]
12. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
[TBL] [Abstract][Full Text] [Related]
14. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
[TBL] [Abstract][Full Text] [Related]
16. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease.
Zhao N; Jiang W; Wu H; Wang P; Wang X; Bai Y; Li Y; Tang Y; Liu Y
Front Immunol; 2022; 13():872615. PubMed ID: 36032132
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).
Mejía M; Herrera-Bringas D; Pérez-Román DI; Rivero H; Mateos-Toledo H; Castorena-García P; Figueroa JE; Rojas-Serrano J
Respir Med; 2017 Feb; 123():79-86. PubMed ID: 28137500
[TBL] [Abstract][Full Text] [Related]
18. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use.
Stanciu R; Guiguet M; Musset L; Touitou D; Beigelman C; Rigolet A; Costedoat-Chalumeau N; Allenbach Y; Hervier B; Dubourg O; Maisonobe T; Charuel JL; Behin A; Herson S; Amoura Z; Grenier P; Benveniste O
J Rheumatol; 2012 Sep; 39(9):1835-9. PubMed ID: 22859355
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.
Andersson H; Aaløkken TM; Günther A; Mynarek GK; Garen T; Lund MB; Molberg Ø
J Rheumatol; 2016 Jun; 43(6):1107-13. PubMed ID: 27036381
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience.
Zhang D; Wang H; Zhou X; Yang J; Liu Y; Wang W; Jiang P; Fan B
Immun Inflamm Dis; 2023 Nov; 11(11):e1085. PubMed ID: 38018600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
